From: The NLRP3 inflammasome: an emerging therapeutic target for chronic pain
Pain condition | Species | Administration route | Administration dosage | Dosage regimen | References |
---|---|---|---|---|---|
Oxaliplatin-induced CIPN | SD rats | i.t. | 5 μmol/day | Once daily for 25 consecutive days | [30] |
CPIP | SD rats | i.t. | 30 μg/rat | Once daily for 7 consecutive days | [31] |
RR-EAE | C57 mice | i.g. | 50 mg/kg | Once daily for 21 consecutive days | [32] |
FSL1-induced inflammatory pain | C57 mice | i.p. | 10 mg/kg | Single dose | [33] |
NTG-induced migraine | C57 mice | i.p. | 10 mg/kg | Once daily for 11 consecutive days | [34] |
EAP | NOD/LtJ non-obese diabetic (NOD) mice | i.p. | 10 mg/kg | Once a day or every other day for a total of 7 treatments | [35] |
BCP | SD rats | i.p. | 5 mg/kg; 10 mg/kg | For acute treatment: single dose | [15] |
 | 5 mg/kg; 10 mg/kg | For chronic treatment: once daily for 5 consecutive days | |||
Morphine- or fentanyl-induced hyperalgesia | Wistar rats | i.p. | 5 mg/kg | Once daily for 7 consecutive days | [24] |